*IMS Health, US total prescriptions for DETROL LA from 2001 to 2012.
SDI Total Patient Tracker data for DETROL LA from 2002 to 2012.
Terms and Conditions apply.

Indication

DETROL® LA (tolterodine tartrate extended release capsules) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Important Safety Information

DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. DETROL LA is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate.

Anaphylaxis and angioedema requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of DETROL LA. In the event of difficulty in breathing, upper airway obstruction, or fall in blood pressure, DETROL LA should be discontinued and appropriate therapy promptly provided.

DETROL LA capsules should be used with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, myasthenia gravis, and QTc prolongation.

DETROL LA is associated with anticholinergic central nervous system (CNS) effects including dizziness and somnolence. Advise patients not to drive or operate heavy machinery until DETROL LA effects have been determined. Consider dose reduction or drug discontinuation if a patient experiences anticholinergic CNS effects.

The recommended dose of DETROL LA capsules is 4 mg once daily swallowed whole. For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), or severe renal impairment (CCr 10-30 mL/min), the recommended starting dose is 2 mg once daily. DETROL LA is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). Patients with CCr <10 mL/min have not been studied and use of DETROL LA is not recommended.

The most frequently reported adverse events (≥4%) for DETROL LA were: dry mouth (placebo, 8%; DETROL LA, 23%), headache (placebo, 4%; DETROL LA, 6%), constipation (placebo, 4%; DETROL LA, 6%), and abdominal pain (placebo, 2%; DETROL LA, 4%).

DETROL LA $4 Co-Pay Savings Card Terms and Conditions

By participating in the DETROL LA Savings Card Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  • The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”)
  • The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs, which reimburse you for the entire cost of your prescription drugs
  • Patients must be 18 or older
  • You must deduct the savings received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
  • Eligible patients will pay a minimum of $4 per prescription fill. By using the Card eligible patients will receive a savings of up to $75 per fill off their co-pay or out-of-pocket costs. The Card is good for a maximum savings of $900 per year ($75 per month x 12 months). The Card limits your prescription cost to $4, subject to a maximum $75 monthly benefit. Thus, if your co-pay or out-of-pocket cost is more than $79 you will save $75 off of your co-pay or total out-of-pocket costs. [Example: If your co-pay or out-of-pocket costs are $100, you will pay $25 ($100-$75=$25)]. If your co-pay or out-of-pocket costs are no more than $79, you pay $4. For a mail-order 3-month prescription, your total maximum savings will be $225 (75x3)
  • The Card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law
  • The Card cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • The Card will be accepted only at participating pharmacies
  • The Card is not health insurance
  • This offer is good only in the U.S. and Puerto Rico
  • The Card is limited to one per person during this offering period and is not transferable
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice at any time
  • No membership fees. The Card and Program expire on 12/31/15

Visit www.DetrolLA.com for more information about DETROL LA. For help with the DETROL LA Savings Card Program, call 1-855-541-5932, or write: DETROL LA Savings Program, 14001 Weston Parkway, Suite 103, Cary, NC 27513. Be sure to include your name and mailing address.

Please scroll for Important Safety Information and Indication

Important Safety Information

DETROL® LA (tolterodine tartrate extended release capsules) is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. DETROL LA is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate.

Anaphylaxis and angioedema requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of DETROL LA. In the event of difficulty in breathing, upper airway obstruction, or fall in blood pressure, DETROL LA should be discontinued and appropriate therapy promptly provided.

DETROL LA capsules should be used with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, myasthenia gravis, and QTc prolongation.

DETROL LA is associated with anticholinergic central nervous system (CNS) effects including dizziness and somnolence. Advise patients not to drive or operate heavy machinery until DETROL LA effects have been determined. Consider dose reduction or drug discontinuation if a patient experiences anticholinergic CNS effects.

The recommended dose of DETROL LA capsules is 4 mg once daily swallowed whole. For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), or severe renal impairment (CCr 10-30 mL/min), the recommended starting dose is 2 mg once daily. DETROL LA is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). Patients with CCr <10 mL/min have not been studied and use of DETROL LA is not recommended.

The most frequently reported adverse events (≥4%) for DETROL LA were: dry mouth (placebo, 8%; DETROL LA, 23%), headache (placebo, 4%; DETROL LA, 6%), constipation (placebo, 4%; DETROL LA, 6%), and abdominal pain (placebo, 2%; DETROL LA, 4%).

Indication

DETROL LA is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.